Tests a new PET/MR scan with a tracer to image multiple myeloma
Tests a new combined scan using a tracer in adults with multiple myeloma.
Plain-language title generated from the registry record
Registry title: PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)
Key facts
- Where
- Toronto, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma. It tests a PET/MR scan with a new tracer, [68Ga]Ga-PentixaFor, against standard imaging.
- Age
- Older than 18 years
- Sex
- All sexes can join
- Disease stage
- Clinical diagnosis of multiple myeloma by IMWG criteria, including nonsecretory, oligosecretory or suspected extramedullary disease
- Earlier treatment
- The record says no treatment beyond the first course, but the text is cut off
Main reasons for not taking part
- Any reason that rules out MRI or 18F-FDG PET/CT
- Pregnancy or breastfeeding
- Cannot lie still for at least 30 minutes
- Unwilling to use contraception during the study
- Allergy to [68Ga]Ga-PentixaFor or another blood cancer diagnosed at the same time
Read by machine on 9 November 2026.
Where in Canada
- University Health NetworkToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT06871176
- Record updated
- 1 October 2026
- Original description
Multiple myeloma is a disease mainly located in participants bones. Usually a participants physician arrives at this diagnosis by doing blood tests and ordering standard of care imaging tests (18F-FDG PET/CT and maybe additional MRI) to see how many bones (and/or other organs) are affected. While these two imaging tests are already very good, recent research indicates that even more precise imaging methods could be used to diagnose participants disease more precisely.Read full original descriptionShow less
[68Ga]Ga-PentixaFor (CXCR4) PET/MR for Initial Staging and Follow up in Multiple Myeloma: Prospective Comparison With Standard of Care PET/CT and Evaluation of Therapy Influence
Multiple myeloma is a disease mainly located in participants bones. Usually a participants physician arrives at this diagnosis by doing blood tests and ordering standard of care imaging tests (18F-FDG PET/CT and maybe additional MRI) to see how many bones (and/or other organs) are affected. While these two imaging tests are already very good, recent research indicates that even more precise imaging methods could be used to diagnose participants disease more precisely.
The purpose of this study is to learn if a combined PET/MR scan with a new radiotracer, [68Ga]Ga-PentixaFor, can provide more accurate and precise diagnostic information in patients with Multiple Myeloma, a type of cancer primarily affecting the bones.
This study aims to improve the accuracy of diagnosing and monitoring Multiple Myeloma using more advanced imaging techniques.
Inclusion: Patient older than 18 years of age; Clinical diagnosis of (nonsecretory, oligosecretory, suspicion for extramedullary MM) MM. MM diagnosis is based on IMWG (International Myeloma Working Group) criteria.No treatment received beyond first course of.
Exclusion: Any hypersensitivity or known allergy to any component of the investigational product ([68Ga]Ga-PentixaFor)No concomitant other malignant hemato-oncological disease being diagnosed (i.e. additional lymphoma or leukemia); Any contra-indications for MRI or 18F-FDG PET/CT imaging according to institutional guideline; Pregnancy (will be ruled out as per institutional protocol); Inability to lie still in prone position in MRI for at least 30 min or PET/CT for at least 30 min; Patients or unwilling to use contraception during study and breastfeeding women can also not partake in this study; Inability to provide consent.